Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... FRANCISCO and WASHINGTON , ... clinical-stage cancer biotherapeutics company, today reported positive results from ... (IV) administration of JX-594 to patients with metastatic cancer. ... solid tumors, cancer-targeted replication and gene expression, and anti-cancer ...
... and SAN DIEGO , May 20 ... genomic research organization, published results today describing the successful construction ... the 1.08 million base pair chromosome of a modified ... Mycoplasma mycoides JCVI-syn1.0 and is the proof of principle ...
... ... Scientists Can Focus on Novel Research , ... (PRWEB) May 20, 2010 -- DNA2.0 , the leading gene synthesis and ... order to provide customers with a seamless experience from gene synthesis to protein expression and ...
Cached Biology Technology:Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 2Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 4First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 2First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 3First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 4First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 5First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 6First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers 7DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 2DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 3
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
(Date:4/17/2014)... Orange, NJ. April 16, 2014. Kessler Foundation has ... $1.8 million from the Department of Defense Spinal ... is principal investigator for the randomized, double-blinded, controlled, ... improve bone and muscle strength after spinal cord ... Performance & Engineering Research at Kessler Foundation. Two ...
(Date:4/17/2014)... available in German . ... objects; they also provide us with a continuous stream of ... fall or sit still in a car the world ... our retinas. Seemingly without effort, our brain calculates self-motion from ... position and a steady gaze during our own movements. Together ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... Uniformed Services University of the Health Sciences (USU) suggests ... that protects against the myriad strains of the HIV ... may need to stimulate the body to produce cross-reactive ... demonstrate that induction of truly broad-spectrum neutralizing antibodies may ...
... (IPF) is a chronic lung disease typically characterized by ... or cough. Most patients live about five years after ... today in the online journal PLoS ONE, a subset ... much more rapid progression to complete pulmonary failure and ...
... for other mothers' kids. , An intriguing study of ... Alberta in Edmonton, Canada and the University of Lethbridge, also ... distress calls of fawns, similar to the responses elicited when ... whitetail and mule deer calls, even when their own fawn ...
Cached Biology News:Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients 2Mule deer moms rescue other fawns 2
... Precipitation Kit is designed for concentration ... aqueous samples. Proteomics sample analysis is ... non-protein impurities such as buffers, salts ... that interfere with electrophoretic separations or ...
... carrier proteins to simplify the production ... Carrier Proteins are commonly used carriers ... heterobifunctional cross-linker (Sulfo-SMCC). This activation results ... Thus allowing the maleimide-activated carrier ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: